3D Liver Fibrosis Models in Lab: A Novel Modality for Drug Screening

Area of Science:

• Hepatology and Regenerative Medicine
• Biomedical Engineering
• Drug Discovery and Toxicology

Background:

• Liver fibrosis is a critical pathological process resulting from chronic liver injury, potentially leading to cirrhosis and hepatocellular carcinoma.
• Despite extensive research, the intricate cellular and molecular mechanisms driving liver fibrosis remain incompletely elucidated.
• Effective therapeutic strategies are hindered by the lack of ideal in vitro models for comprehensive study and drug screening.

Purpose of the Study:

• To review and introduce available in vitro models for investigating liver fibrosis.
• To highlight advanced platforms like organoids and liver-on-a-chip for liver fibrosis research.
• To discuss the challenges and potential applications of current in vitro models in drug discovery and toxicology.

Main Methods:

• Comprehensive literature review of existing in vitro and in vivo models for liver fibrosis.
• Analysis of emerging technologies such as organoids and liver-on-a-chip systems.
• Evaluation of the suitability of different models for studying fibrosis mechanisms and drug screening.

Main Results:

• Numerous in vitro and in vivo models exist for liver fibrosis research, but none are considered ideal for drug discovery.
• Organoids and liver-on-a-chip platforms show promise for more accurately modeling liver fibrosis.
• Each model presents unique advantages and limitations regarding mechanistic studies and drug screening.

Conclusions:

• In vitro models are essential for understanding liver fibrosis, but current options have limitations.
• Advanced models like organoids and liver-on-a-chip offer improved potential for studying liver fibrosis and developing new therapies.
• Further development of in vitro models is crucial for advancing drug discovery and toxicology in liver fibrosis research.